Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Seattle Genetics, Inc. operates as a biotechnology company. The Company discovers and develops monoclonal antibody-based drugs to treat cancer and related diseases. Seattle Genetics offers antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. Seattle Genetics serves customers in the Pacific Northwest.
Website: seagen.com



Growth: Good revenue growth rate 27.3%, there is acceleration compared to average historical growth rates 22.5%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -45.9%

Profitability: LTM EBITDA margin is negative, -32.0%. On average the margin is improving steadily. Gross margin is high, +74.5%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.09 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -1.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 110.2% higher than minimum and 0.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.2x by EV / Sales multiple , the company can be 93.5% overvalued

Key Financials (Download financials)

Ticker: SGEN
Share price, USD:  (0.0%)228.74
year average price 212.85  


year start price 200.00 2023-04-28

min close price 187.64 2023-05-16

max close price 228.90 2023-12-12

current price 228.74 2024-04-26
Common stocks: 184 676 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  27.3%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  22.5%
Historical growth of EBITDA:  -10.7%
EV / Sales: 17.8x
Margin (EBITDA LTM / Revenue): -32.0%
Fundamental value created in LTM:
Market Cap ($m): 42 243
Net Debt ($m): -1 237
EV (Enterprise Value): 41 006
Price to Book: 16.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-12-01Zacks Investment Research

Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag

2023-11-01Proactive Investors

Seagen 3Q revenue beat driven by jump in product sales

2023-09-25Schaeffers Research

Signal Says Buy Calls on This Biotech Stock

2023-09-25Zacks Investment Research

Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study

2023-08-17Zacks Investment Research

Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal

2023-08-16Reuters

Seagen's breast cancer therapy meets main goal in late-stage study

2023-05-19MarketBeat

Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?

2023-05-17CNBC

Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows

2023-05-17Zacks Investment Research

Pfizer (PFE) to Raise $31B in Debt to Fund Seagen (SGEN) Deal

2023-05-17Barrons

Pfizer Prices $31 Billion Debt Offering to Fund Seagen Acquisition
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SGEN SGEN SGEN SGEN SGEN
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2023-11-01 2023-08-02 2023-04-27 2023-02-15 2022-10-27
acceptedDate 2023-11-01 08:31:54 2023-08-02 08:30:57 2023-04-27 08:33:38 2023-02-15 17:18:25 2022-10-27 17:10:06
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
revenue 649M 604M 520M 528M 510M
costOfRevenue 165M 181M 112M 108M 108M
grossProfit 483M 423M 408M 420M 402M
grossProfitRatio 0.745 0.701 0.785 0.795 0.788
researchAndDevelopmentExpenses 449M 400M 356M 358M 385M
generalAndAdministrativeExpenses 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 266M 244M 236M 216M 210M
otherExpenses 0 0 0 0 0
operatingExpenses 715M 644M 592M 574M 595M
costAndExpenses 880M 825M 704M 682M 703M
interestIncome 14M 15M 0 0 0
interestExpense 0 0 -51M -41M 0
depreciationAndAmortization 23M -12M -14M -10M 25M
ebitda -223M -233M -199M -164M -168M
ebitdaratio -0.344 -0.386 -0.383 -0.311 -0.329
operatingIncome -231M -221M -185M -154M -193M
operatingIncomeRatio -0.357 -0.366 -0.355 -0.292 -0.378
totalOtherIncomeExpensesNet 15M 12M 14M 10M 4M
incomeBeforeTax -216M -209M -170M -144M -189M
incomeBeforeTaxRatio -0.334 -0.346 -0.327 -0.272 -0.369
incomeTaxExpense -571 000 3M 5M 4M 2M
netIncome -216M -212M -175M -148M -191M
netIncomeRatio -0.333 -0.350 -0.336 -0.281 -0.374
eps -1.150 -1.130 -0.930 -0.800 -1.030
epsdiluted -1.150 -1.130 -0.930 -0.800 -1.030
weightedAverageShsOut 188M 188M 187M 186M 185M
weightedAverageShsOutDil 188M 188M 187M 186M 185M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SGEN SGEN SGEN SGEN SGEN
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2023-11-01 2023-08-02 2023-04-27 2023-02-15 2022-10-27
acceptedDate 2023-11-01 08:31:54 2023-08-02 08:30:57 2023-04-27 08:33:38 2023-02-15 17:18:25 2022-10-27 17:10:06
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 429M 308M 336M 320M 363M
shortTermInvestments 808M 984M 1 154M 1 415M 1 401M
cashAndShortTermInvestments 1 237M 1 292M 1 490M 1 735M 1 764M
netReceivables 632M 586M 496M 502M 487M
inventory 531M 487M 478M 427M 365M
otherCurrentAssets 152M 151M 137M 138M 144M
totalCurrentAssets 2 552M 1 292M 1 490M 1 735M 2 760M
propertyPlantEquipmentNet 488M 428M 379M 295M 280M
goodwill 275M 275M 275M 275M 275M
intangibleAssets 220M 226M 232M 238M 243M
goodwillAndIntangibleAssets 495M 501M 506M 512M 518M
longTermInvestments 1M 613 000 0 0 0
taxAssets -1M -613 000 0 0 0
otherNonCurrentAssets 100M 1 274M 1 168M 1 132M 62M
totalNonCurrentAssets 1 083M 2 203M 2 053M 1 939M 859M
otherAssets 0 0 0 0 0
totalAssets 3 634M 3 495M 3 543M 3 675M 3 619M
accountPayables 225M 114M 141M 208M 144M
shortTermDebt 0 0 0 0 0
taxPayables 0 0 0 0 0
deferredRevenue 0 0 0 0 0
otherCurrentLiabilities 730M 648M 572M 611M 581M
totalCurrentLiabilities 955M 763M 713M 818M 726M
longTermDebt 113M 97M 91M 43M 47M
deferredRevenueNonCurrent 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0
otherNonCurrentLiabilities 16M 16M 16M 9M -73M
totalNonCurrentLiabilities 129M 113M 107M 52M 71M
otherLiabilities 0 0 0 0 0
capitalLeaseObligations 113M 97M 91M 43M 47M
totalLiabilities 1 084M 876M 820M 871M 797M
preferredStock 0 0 0 0 0
commonStock 189 000 188 000 187 000 187 000 185 000
retainedEarnings -2 756M -2 541M -2 329M -2 154M -2 006M
accumulatedOtherComprehensiveIncomeLoss 4M 4M 4M 4M 3M
othertotalStockholdersEquity 5 302M 5 155M 5 048M 4 954M 4 825M
totalStockholdersEquity 2 550M 2 619M 2 723M 2 804M 2 822M
totalEquity 2 550M 2 619M 2 723M 2 804M 2 822M
totalLiabilitiesAndStockholdersEquity 3 634M 3 495M 3 543M 3 675M 3 619M
minorityInterest 0 0 0 0 0
totalLiabilitiesAndTotalEquity 3 634M 3 495M 3 543M 3 675M 3 619M
totalInvestments 808M 984M 1 154M 1 415M 1 401M
totalDebt 113M 97M 91M 43M 47M
netDebt -315M -211M -245M -276M -316M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SGEN SGEN SGEN SGEN SGEN
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2023-11-01 2023-08-02 2023-04-27 2023-02-15 2022-10-27
acceptedDate 2023-11-01 08:31:54 2023-08-02 08:30:57 2023-04-27 08:33:38 2023-02-15 17:18:25 2022-10-27 17:10:06
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
netIncome -216M -212M -175M -148M -191M
depreciationAndAmortization 23M 22M 22M 21M 21M
deferredIncomeTax 286 000 338 000 211 000 774 000 336 000
stockBasedCompensation 131M 93M 64M 64M 59M
changeInWorkingCapital 37M -117M -150M -12M 24M
accountsReceivables -46M -90M 6M -15M -49M
inventory -44M -56M -50M -62M -46M
accountsPayables 0 0 0 0 0
otherWorkingCapital 127M 29M -106M 66M 118M
otherNonCashItems -12M 38M -11M -6M 1M
netCashProvidedByOperatingActivities -36M -175M -250M -79M -86M
investmentsInPropertyPlantAndEquipment -44M -49M -39M -29M -16M
acquisitionsNet 0 0 0 0 0
purchasesOfInvestments -574M -507M -618M -402M -571M
salesMaturitiesOfInvestments 761M 690M 892M 397M 656M
otherInvestingActivites -227 000 -369 000 -2M -2M -4M
netCashUsedForInvestingActivites 142M 133M 232M -36M 65M
debtRepayment 0 0 0 0 0
commonStockIssued 0 0 42M 125M 0
commonStockRepurchased 0 0 0 0 0
dividendsPaid 0 0 0 0 0
otherFinancingActivites 16M 14M -12M -60M 18M
netCashUsedProvidedByFinancingActivities 16M 14M 30M 65M 18M
effectOfForexChangesOnCash -2M 566 000 920 000 6M -4M
netChangeInCash 120M -28M 14M -45M -6M
cashAtEndOfPeriod 429M 309M 337M 323M 368M
cashAtBeginningOfPeriod 309M 337M 323M 368M 375M
operatingCashFlow -36M -175M -250M -79M -86M
capitalExpenditure -44M -49M -39M -29M -16M
freeCashFlow -80M -224M -288M -109M -102M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

2022 q4
2023-02-15 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2023-12-15 22:00 ET
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
2023-12-14 12:39 ET
Pfizer Completes Acquisition of Seagen
2023-12-12 11:45 ET
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
2023-12-11 00:30 ET
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
2023-12-06 13:15 ET
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
2023-11-30 22:00 ET
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
2023-11-30 22:00 ET
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
2023-11-03 16:00 ET
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2023-11-02 17:00 ET
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
2023-11-01 12:00 ET
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
2023-10-22 14:30 ET
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
2023-10-22 14:30 ET
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
2023-10-22 14:30 ET
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
2023-10-16 12:00 ET
Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023
2023-10-12 12:00 ET
Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023
2023-10-10 16:00 ET
Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies
2023-09-22 09:00 ET
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
2023-09-22 09:00 ET
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
2023-09-04 19:00 ET
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
2023-08-16 12:00 ET
Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
2023-08-02 12:00 ET
Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
2023-07-12 12:00 ET
Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023
2023-06-20 12:30 ET
Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma
2023-06-15 00:31 ET
Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
2023-06-13 07:01 ET
Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)
2023-05-30 19:22 ET
Seagen Stockholders Approve Acquisition by Pfizer
2023-04-27 12:00 ET
Seagen Reports First Quarter 2023 Financial Results
2023-04-26 14:48 ET
Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
2023-04-07 12:00 ET
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
2023-04-03 21:00 ET
FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
2023-04-03 21:00 ET
FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
2023-03-14 20:30 ET
Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
2023-03-13 10:45 ET
Pfizer Invests $43 Billion to Battle Cancer
2023-03-09 23:30 ET
Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
2023-03-09 23:30 ET
Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
2023-02-27 13:00 ET
Seagen to Present at the Cowen 43rd Annual Health Care Conference
2023-02-15 21:02 ET
Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-13 22:00 ET
Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
2023-01-19 19:21 ET
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
2023-01-19 13:00 ET
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
2022-12-20 13:00 ET
Seagen to Present at the J.P. Morgan Healthcare Conference
2022-12-20 11:45 ET
Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic...
2022-12-20 11:45 ET
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
2022-12-12 15:00 ET
Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
2022-12-01 13:30 ET
Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
2022-11-10 18:12 ET
Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
2022-11-10 14:00 ET
Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
2022-11-10 12:05 ET
Seagen Appoints Sandra M. Swain, M.D., to Board of Directors
2022-11-10 12:00 ET
Seagen Names David R. Epstein as Chief Executive Officer and Director
2022-10-27 20:02 ET
Seagen Reports Third Quarter 2022 Financial Results
2022-10-06 12:00 ET
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022
2022-09-27 12:00 ET
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
2022-09-27 12:00 ET
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
2022-09-26 12:00 ET
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
2022-09-26 12:00 ET
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
2022-09-19 12:00 ET
Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer
2022-09-12 12:55 ET
Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
2022-09-12 12:55 ET
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
2022-09-07 22:05 ET
Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress
2022-09-07 12:00 ET
Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-12 17:14 ET
Seagen Statement on Outcome of Daiichi Sankyo Arbitration
2022-07-28 20:02 ET
Seagen Reports Second Quarter 2022 Financial Results
2022-07-26 08:00 ET
Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
2022-07-26 08:00 ET
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
2022-07-08 12:00 ET
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022
2022-07-02 10:35 ET
Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer
2022-06-06 15:00 ET
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
2022-06-03 19:12 ET
ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
2022-05-26 21:25 ET
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
2022-05-23 12:00 ET
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
2022-05-16 10:00 ET
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
2022-05-09 10:00 ET
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
2022-04-28 20:02 ET
Seagen Reports First Quarter 2022 Financial Results
2022-04-28 12:00 ET
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-04-20 13:00 ET
Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
2022-04-13 15:45 ET
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
2022-04-13 15:45 ET
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
2022-04-08 19:23 ET
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
2022-04-08 17:19 ET
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
2022-04-07 12:00 ET
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
2022-03-16 10:30 ET
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
2022-03-01 13:00 ET
Seagen to Present at the Cowen 42nd Annual Health Care Conference
2022-02-28 13:00 ET
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
2022-02-28 13:00 ET
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
2022-02-24 15:00 ET
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
2022-02-14 22:00 ET
Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
2022-02-14 22:00 ET
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
2022-02-09 21:02 ET
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-08 13:00 ET
Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2022-02-03 13:00 ET
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
2022-02-01 13:00 ET
Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
2022-01-18 22:00 ET
Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
2022-01-18 13:00 ET
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
2021-12-20 13:00 ET
Seagen to Present at the J.P. Morgan Healthcare Conference
2021-12-17 11:40 ET
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
2021-12-17 11:40 ET
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
2021-12-12 23:00 ET
Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymphoma
2021-12-08 23:00 ET
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases
2021-11-19 14:33 ET
Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium
2021-11-09 13:54 ET
Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting
2021-11-04 13:31 ET
Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting
2021-10-28 20:02 ET
Seagen Reports Third Quarter 2021 Financial Results
2021-10-12 12:00 ET
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
2021-10-12 12:00 ET
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
2021-10-07 12:00 ET
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
2021-09-28 12:00 ET
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
2021-09-27 07:00 ET
Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
2021-09-27 07:00 ET
Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
2021-09-20 21:05 ET
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval
2021-09-20 21:00 ET
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
2021-09-19 15:30 ET
Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
2021-09-09 12:00 ET
Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
2021-09-08 12:00 ET
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
2021-08-09 10:00 ET
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
2021-07-29 20:02 ET
Seagen Reports Second Quarter 2021 Financial Results
2021-07-09 18:10 ET
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
2021-07-09 18:10 ET
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
2021-07-08 12:00 ET
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021
2021-06-03 10:00 ET
Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting
2021-06-02 12:00 ET
Seagen to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-19 21:04 ET
Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
2021-05-19 21:00 ET
Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
2021-04-29 20:02 ET
Seagen Reports First Quarter 2021 Financial Results
2021-04-29 12:00 ET
Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting
2021-04-19 12:00 ET
Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
2021-04-19 12:00 ET
Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
2021-04-09 20:00 ET
 Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
2021-04-09 12:00 ET
Seagen to Highlight Data from Novel Targeted Therapies at AACR
2021-04-07 12:00 ET
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2021 Financial Results on April 29, 2021
2021-03-26 06:00 ET
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
2021-03-26 06:00 ET
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
2021-03-05 13:00 ET
Seagen Recommends Rejection Of 'Mini-Tender' Offer from TRC Capital Investment Corporation
2021-02-24 13:00 ET
Seagen to Present at the Cowen 41st Annual Healthcare Conference
2021-02-18 13:00 ET
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
2021-02-18 13:00 ET
Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
2021-02-12 19:15 ET
Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
2021-02-12 19:15 ET
Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy
2021-02-12 19:15 ET
Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy
2021-02-12 19:15 ET
Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
2021-02-12 11:45 ET
European Commission Approves Seagen’s TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
2021-02-11 21:02 ET
Seagen Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-10 21:05 ET
Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
2021-01-07 13:00 ET
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
2020-12-16 13:00 ET
Seagen to Present at the J.P. Morgan Healthcare Conference
2020-12-11 13:00 ET
Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors
2020-12-11 12:23 ET
Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
2020-12-08 13:00 ET
Seagen Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer Symposium
2020-12-07 15:00 ET
Seagen Announces Multiple ADCETRIS® (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting
2020-11-09 13:00 ET
Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020
2020-11-05 13:00 ET
Seagen Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting
2020-11-02 13:00 ET
Seagen to Host Virtual R&D Day on November 16, 2020
2020-10-29 20:02 ET
Seagen Reports Third Quarter 2020 Financial Results
2020-10-28 12:00 ET
Seagen Announces Closing of $1.0 Billion Stock Sale to Merck
2020-10-13 12:00 ET
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2020 Financial Results on October 29, 2020
2020-10-12 10:45 ET
Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
2020-10-12 10:45 ET
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
2020-10-08 12:00 ET
Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc.
2020-09-21 14:20 ET
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
2020-09-18 10:45 ET
Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
2020-09-18 10:45 ET
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
2020-09-14 10:45 ET
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
2020-09-03 12:00 ET
Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-08-27 12:10 ET
Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin)
2020-08-27 12:00 ET
Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020
2020-08-18 12:00 ET
Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors
2020-08-12 12:00 ET
Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative
2020-08-06 12:00 ET
Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval
2020-07-30 20:02 ET
Seattle Genetics Reports Second Quarter 2020 Financial Results
2020-07-09 12:00 ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020
2020-06-29 20:30 ET
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
2020-06-18 12:00 ET
Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates
2020-06-03 12:00 ET
Seattle Genetics to Present at Goldman Sachs 41st Annual Global Healthcare Conference
2020-05-29 12:00 ET
Seattle Genetics Announces Positive Results from Exploratory Analyses of HER2CLIMB for TUKYSA™ (tucatinib) in Brain Metastases Patients With HER2-Positive Breast Cancer
2020-05-18 12:00 ET
Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24, 2020
2020-05-14 12:00 ET
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma
2020-05-13 21:12 ET
Seattle Genetics Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO Annual Meeting
2020-05-12 12:00 ET
Seattle Genetics Announces the Approval of TUKYSA™ (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer
2020-05-05 12:00 ET
Seattle Genetics to Present at the BofA Securities Virtual Health Care Conference 2020
2020-04-30 20:02 ET
Seattle Genetics Reports First Quarter 2020 Financial Results
2020-04-24 12:00 ET
Seattle Genetics Announces Change to Virtual Format for 2020 Annual Meeting
2020-04-17 18:27 ET
Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
2020-04-13 12:00 ET
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2020 Financial Results on April 30, 2020
2020-04-08 12:00 ET
Seattle Genetics to Webcast Virtual Fireside Chat at Needham Healthcare Conference
2020-04-02 12:00 ET
Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
2020-03-10 12:00 ET
Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference
2020-03-02 13:00 ET
Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference
2020-02-26 13:00 ET
Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference
2020-02-19 13:12 ET
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
2020-02-13 13:00 ET
Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
2020-02-11 13:00 ET
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer
2020-02-06 21:02 ET
Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results
2020-01-31 13:00 ET
EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
2020-01-21 13:30 ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020
2020-01-21 13:00 ET
Seattle Genetics Achieves Milestone Following European Commission Approval of Roche’s Polivy® (Polatuzumab Vedotin)
2020-01-06 13:00 ET
Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
2019-12-23 13:00 ET
Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
2019-12-18 23:42 ET
Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Approval
2019-12-18 23:36 ET
FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer
2019-12-18 13:00 ET
Seattle Genetics Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
2019-12-11 14:54 ET
Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of Medicine
2019-12-09 15:00 ET
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
2019-12-07 19:00 ET
Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
2019-12-02 13:00 ET
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
2019-12-02 13:00 ET
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
2019-11-25 13:00 ET
Seattle Genetics Announces Health Canada Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
2019-11-12 22:15 ET
Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership
2019-11-07 13:00 ET
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting
2019-11-05 04:51 ET
Seattle Genetics Responds to Daiichi Sankyo’s Complaint for Declaratory Judgment
2019-11-04 13:00 ET
Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference
2019-10-29 20:02 ET
Seattle Genetics Reports Third Quarter 2019 Financial Results
2019-10-21 10:45 ET
Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
2019-10-10 12:00 ET
Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer
2019-10-08 12:00 ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2019 Financial Results on October 29, 2019
2019-09-29 13:00 ET
Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer
2019-09-28 06:30 ET
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
2019-09-28 06:30 ET
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
2019-09-17 12:00 ET
Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress
2019-09-16 12:00 ET
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
2019-09-16 12:00 ET
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
2019-07-16 12:00 ET
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

SEC forms

Show financial reports only

SEC form 10
2023-11-01 08:31 ET
Seattle Genetics published news for 2023 q3
SEC form 8
2023-11-01 08:09 ET
Seattle Genetics reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Seattle Genetics published news for 2023 q3
SEC form 10
2023-08-02 08:30 ET
Seattle Genetics reported for 2023 q2
SEC form 6
2023-08-02 08:11 ET
Seattle Genetics published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Seattle Genetics published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Seattle Genetics published news for 2023 q2
SEC form 6
2023-07-14 17:15 ET
Seattle Genetics published news for 2023 q2
SEC form 6
2023-06-14 06:05 ET
Seattle Genetics published news for 2023 q1
SEC form 6
2023-06-01 08:11 ET
Seattle Genetics published news for 2023 q1
SEC form 6
2023-05-31 17:25 ET
Seattle Genetics published news for 2023 q1
SEC form 10
2023-04-27 00:00 ET
Seattle Genetics published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
Seattle Genetics published news for 2023 q1
SEC form 6
2023-04-03 17:26 ET
Seattle Genetics published news for 2023 q1
SEC form 6
2023-03-13 07:27 ET
Seattle Genetics published news for 2022 q4
SEC form 10
2023-02-15 17:18 ET
Seattle Genetics reported for 2022 q4
SEC form 6
2023-02-15 16:11 ET
Seattle Genetics published news for 2022 q4
SEC form 10
2023-02-15 00:00 ET
Seattle Genetics reported for 2022 q4
SEC form 8
2023-02-15 00:00 ET
Seattle Genetics reported for 2022 q4
SEC form 6
2023-01-19 15:37 ET
Seattle Genetics published news for 2022 q4
SEC form 6
2022-11-18 16:47 ET
Seattle Genetics published news for 2022 q3
SEC form 6
2022-11-10 19:39 ET
Seattle Genetics published news for 2022 q3
SEC form 6
2022-11-10 19:28 ET
Seattle Genetics published news for 2022 q3
SEC form 6
2022-11-10 07:31 ET
Seattle Genetics published news for 2022 q3
SEC form 10
2022-10-27 17:10 ET
Seattle Genetics reported for 2022 q3
SEC form 6
2022-10-27 16:04 ET
Seattle Genetics published news for 2022 q3
SEC form 10
2022-10-27 00:00 ET
Seattle Genetics reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Seattle Genetics reported for 2022 q3
SEC form 6
2022-08-12 15:06 ET
Seattle Genetics published news for 2022 q2
SEC form 10
2022-07-28 17:20 ET
Seattle Genetics reported for 2022 q2
SEC form 6
2022-07-28 16:05 ET
Seattle Genetics published news for 2022 q2
SEC form 10
2022-07-28 00:00 ET
Seattle Genetics reported for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Seattle Genetics reported for 2022 q2
SEC form 6
2022-07-26 06:10 ET
Seattle Genetics published news for 2022 q2
SEC form 6
2022-06-01 16:08 ET
Seattle Genetics published news for 2022 q1
SEC form 6
2022-05-23 08:11 ET
Seattle Genetics published news for 2022 q1
SEC form 6
2022-05-19 16:47 ET
Seattle Genetics published news for 2022 q1
SEC form 6
2022-05-17 19:35 ET
Seattle Genetics published news for 2022 q1
SEC form 6
2022-05-17 19:33 ET
Seattle Genetics published news for 2022 q1
SEC form 6
2022-05-17 19:32 ET
Seattle Genetics published news for 2022 q1
SEC form 6
2022-05-16 06:10 ET
Seattle Genetics published news for 2022 q1
SEC form 6
2022-05-09 06:07 ET
Seattle Genetics published news for 2022 q1
SEC form 10
2022-04-28 17:00 ET
Seattle Genetics reported for 2022 q1
SEC form 6
2022-04-28 16:04 ET
Seattle Genetics published news for 2022 q1
SEC form 10
2022-04-28 00:00 ET
Seattle Genetics reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Seattle Genetics reported for 2022 q1
SEC form 6
2022-04-15 16:35 ET
Seattle Genetics published news for 2022 q1
SEC form 6
2022-04-08 17:02 ET
Seattle Genetics published news for 2022 q1
SEC form 6
2022-03-30 16:07 ET
Seattle Genetics published news for 2021 q4
SEC form 6
2022-03-11 16:54 ET
Seattle Genetics published news for 2021 q4
SEC form 6
2022-03-04 17:09 ET
Seattle Genetics published news for 2021 q4
SEC form 6
2022-02-11 17:19 ET
Seattle Genetics published news for 2021 q4
SEC form 10
2022-02-09 17:27 ET
Seattle Genetics published news for 2021 q4
SEC form 6
2022-02-09 16:03 ET
Seattle Genetics published news for 2021 q4
SEC form 8
2022-02-09 00:00 ET
Seattle Genetics published news for 2021 q4
SEC form 10
2022-02-09 00:00 ET
Seattle Genetics published news for 2021 q4
SEC form 6
2022-01-19 18:26 ET
Seattle Genetics published news for 2021 q4
SEC form 6
2021-11-23 18:49 ET
Seattle Genetics published news for 2021 q3
SEC form 10
2021-10-28 17:10 ET
Seattle Genetics published news for 2021 q3
SEC form 6
2021-10-28 16:03 ET
Seattle Genetics published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
Seattle Genetics published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Seattle Genetics published news for 2021 q3
SEC form 6
2021-09-21 16:34 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-09-20 19:33 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-09-02 20:07 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-09-02 19:59 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-09-02 19:58 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-09-02 19:57 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-09-02 19:53 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-09-02 19:49 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-08-09 06:14 ET
Seattle Genetics published news for 2021 q2
SEC form 10
2021-07-29 17:19 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-07-29 16:04 ET
Seattle Genetics published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Seattle Genetics published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-07-15 16:23 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-07-09 17:17 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-07-06 21:40 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-07-06 20:13 ET
Seattle Genetics published news for 2021 q2
SEC form 6
2021-06-25 16:34 ET
Seattle Genetics published news for 2021 q1
SEC form 6
2021-05-19 16:49 ET
Seattle Genetics published news for 2021 q1
SEC form 10
2021-04-29 17:10 ET
Seattle Genetics published news for 2021 q1
SEC form 6
2021-04-29 16:03 ET
Seattle Genetics published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
Seattle Genetics published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Seattle Genetics published news for 2021 q1
SEC form 6
2021-03-31 17:16 ET
Seattle Genetics published news for 2020 q4
SEC form 10
2021-02-12 07:49 ET
Seattle Genetics published news for 2020 q4
SEC form 6
2021-02-11 16:06 ET
Seattle Genetics published news for 2020 q4
SEC form 6
2020-12-29 16:15 ET
Seattle Genetics published news for 2020 q3
SEC form 10
2020-10-29 18:56 ET
Seattle Genetics published news for 2020 q3
SEC form 6
2020-10-29 16:08 ET
Seattle Genetics published news for 2020 q3
SEC form 6
2020-10-20 06:04 ET
Seattle Genetics published news for 2020 q3
SEC form 6
2020-10-13 07:31 ET
Seattle Genetics published news for 2020 q3
SEC form 6
2020-10-08 08:28 ET
Seattle Genetics published news for 2020 q3